Related Experiment Video
Updated: Aug 15, 2025
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.5K
Atractylodin Ameliorates Colitis via PPARα Agonism
Gwangbeom Heo1, Yuju Kim1, Eun-La Kim1
1College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
International Journal of Molecular Sciences
|January 8, 2023
Summary
Atractylodin, a compound from herbal medicine, shows promise for treating colitis. It reduces inflammation by targeting pathways involving nuclear factor-kappa B and peroxisome proliferator-activated receptor alpha (PPARα).
Area of Science:
- Pharmacology
- Gastroenterology
- Molecular Biology
Background:
- Atractylodin is a key compound in Atractylodes lancea, used traditionally for gastrointestinal issues.
- Emerging research indicates atractylodin possesses anti-inflammatory properties.
- Colitis is a significant inflammatory condition requiring novel therapeutic strategies.
Purpose of the Study:
- To investigate the anti-colitis effects of atractylodin.
- To identify the molecular targets of atractylodin relevant to colitis.
- To evaluate atractylodin's therapeutic potential for colitis.
Main Methods:
- Cell proliferation assays to determine non-cytotoxic concentrations.
- Inhibition assays for tumor necrosis factor-alpha-induced nuclear factor-kappa B activation.
- Molecular docking, luciferase assays, and in vitro binding assays to assess target affinity.
- Dextran sodium sulfate-induced colitis mouse model to evaluate in vivo efficacy.
Main Results:
- Atractylodin (50 μM) was non-cytotoxic to colonic epithelial cells.
- Atractylodin inhibited tumor necrosis factor-alpha-induced nuclear factor-kappa B phosphorylation.
- Atractylodin demonstrated affinity for peroxisome proliferator-activated receptor alpha (PPARα).
- Daily administration of atractylodin (40 mg/kg) improved survival rates in a colitis mouse model.
Conclusions:
- Atractylodin exhibits significant anti-colitis effects.
- The therapeutic action of atractylodin is mediated through PPARα-dependent pathways.
- Atractylodin represents a potential therapeutic agent for colitis management.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
218
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
218
01:17Drugs for Treatment of Diarrhea-Predominant IBS
260
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
260
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
210
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
239
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
239
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188